Citadel Advisors
HRMY icon

Citadel Advisors’s Harmony Biosciences HRMY Stock Holding History

Citadel Advisors’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.57M Sell
56,100
-4,400
-7% -$144K ﹤0.01% 6614
2025
Q4 		$2.26M Sell
60,500
-40,800
-40% -$1.34M ﹤0.01% 5678
2025
Q3 		$2.79M Buy
101,300
+72,900
+257% +$2.51M ﹤0.01% 5432
2025
Q2 		$897K Buy
28,400
+22,200
+358% +$714K ﹤0.01% 7344
2025
Q1 		$206K Sell
6,200
-7,400
-54% -$265K ﹤0.01% 10392
2024
Q4 		$468K Buy
13,600
+12,900
+1,843% +$443K ﹤0.01% 8700
2024
Q3 		$28K Sell
700
-1,500
-68% -$52.7K ﹤0.01% 12497
2024
Q2 		$66.4K Sell
2,200
-5,700
-72% -$171K ﹤0.01% 11442
2024
Q1 		$265K Sell
7,900
-14,800
-65% -$475K ﹤0.01% 9739
2023
Q4 		$733K Buy
22,700
+18,800
+482% +$525K ﹤0.01% 7288
2023
Q3 		$128K Sell
3,900
-3,000
-43% -$104K ﹤0.01% 10589
2023
Q2 		$243K Sell
6,900
-17,000
-71% -$587K ﹤0.01% 9470
2023
Q1 		$780K Buy
23,900
+22,400
+1,493% +$1.02M ﹤0.01% 7330
2022
Q4 		$82.7K Sell
1,500
-84,100
-98% -$4.62M ﹤0.01% 11485
2022
Q3 		$3.79M Buy
85,600
+52,000
+155% +$2.54M ﹤0.01% 4351
2022
Q2 		$1.64M Buy
+33,600
New +$1.51M ﹤0.01% 5962

Other funds holding HRMY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Citadel Advisors's HRMY Position: Q1 2026 in Review

Citadel Advisors increased its Harmony Biosciences (HRMY) stake by 39% in Q1 2026, buying an estimated $5.42M and bringing the position to 585,623 shares worth $16.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2577.

Citadel Advisors first reported a position in HRMY in Q3 2020 and has held it in 22 quarters since. The position peaked at $47.1M in Q4 2024. 309 funds tracked by Wall St. Rank hold HRMY as of Q1 2026.

  • Citadel Advisors held 585,623 shares of Harmony Biosciences worth $16.4M as of Q1 2026.
  • Citadel Advisors bought 165,213 Harmony Biosciences shares in Q1 2026, an estimated $5.42M.
  • Harmony Biosciences made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #2577 holding.
  • Citadel Advisors first reported a position in Harmony Biosciences in Q3 2020 and has held it in 22 quarters since.
  • Citadel Advisors's Harmony Biosciences position peaked at $47.1M in Q4 2024.
  • 309 funds tracked by Wall St. Rank held Harmony Biosciences as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.